We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Lactate Therapy After Traumatic Brain Injury (LS_TCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01573507
Recruitment Status : Completed
First Posted : April 9, 2012
Last Update Posted : September 9, 2021
Swiss National Science Foundation
European Society of Intensive Care Medicine
Information provided by (Responsible Party):
Mauro ODDO, Centre Hospitalier Universitaire Vaudois

Brief Summary:

Background: Although glucose is essential to cerebral function, abundant experimental and clinical evidence demonstrates that endogenously released lactate, rather than glucose, is the preferential energy substrate for the brain in conditions of stress and acute injury. In patients with severe Traumatic Brain Injury (TBI) and aneurysmal subarachnoid hemorrhage (SAH) monitored with cerebral microdialysis and brain tissue oxygen (PbtO2), our preliminary data show that increased brain extracellular lactate is frequently observed. Our findings indicate that elevated brain lactate more often occurs in the absence of brain hypoxia/ischemia and is mainly the consequence of increased cerebral glycolysis, i.e. it occurs in association with high extracellular pyruvate. These data suggest that the primary source of elevated lactate is activated glycolysis and strongly support the concept that endogenously released lactate can be utilized by the injured human brain as energy substrate. They prompt further investigation to examine whether exogenous lactate supplementation can be a valuable neuroprotective strategy after TBI or SAH. Indeed, in animal models of brain injury, administration of exogenous lactate improves neuronal and cognitive recovery.

Hypothesis: The investigators test the hypothesis that lactate therapy, administered during the acute phase of TBI or SAH, might exercise neuroprotective actions by restoring brain energetics and improving brain tissue PO2 and cerebral blood flow (CBF).

Aim of the study: The aim of this single-center study is to examine the effect of sodium lactate infusion on cerebral extracellular metabolites, brain tissue PO2 and cerebral blood flow, measured with CT perfusion and transcranial doppler (TCD).

Design: Prospective phase II interventional study examining the effect of a continuous 3-6 hours infusion of sodium lactate (20-40 µmol/kg/min), administered within 48 hours from TBI or SAH, on cerebral extracellular glucose, pyruvate, glutamate, glycerol, PbtO2 and CBF.

Condition or disease Intervention/treatment Phase
Traumatic Brain Injury Subarachnoid Hemorrhage Other: sodium lactate infusion Not Applicable

Detailed Description:

Study: Prospective, single-centre phase II interventional study. The study will take place at the Department of Intensive Care Medicine, Lausanne University Medical Center (Centre Hospitalier Universitaire Vaudois, CHUV), Lausanne, Switzerland.

Patient population:

Patients will be monitored with an intra-parenchymal monitoring system, consisting of ICP (Codman®, Integra Neurosciences), PbtO2 (Licox®, Integra Neurosciences) and cerebral microdialysis (CMA Microdialysis®) catheters, based on the protocol for management of TBI presently in use at our center.

Each patient will receive a continuous infusion of sodium lactate (composition: lactate 1'000 mmol/L, Na 1'000 mmol/L: concentration 20-40 µmol/kg/min) for 3-6 hours. Sodium lactate will be prepared locally by the Pharmacie Centrale, CHUV, Lausanne.

Each patient will serve as his/her internal control, and the effect of sodium lactate on all brain physiological variables measured will be anayzed before, during and at the end of sodium lactate infusion.

The main parameters of efficacy are increases of MD glucose, MD pyruvate, PbtO2, and CBF, during sodium lactate perfusion.

For both MD glucose and MD pyruvate, we fixed as the minimal detectable effect of sodium lactate infusion a 30% increase of glucose and pyruvate at the end of the study. To obtain a power of 0.8 with an alpha of 0.05, the number of patients required to complete the study is 33. We therefore plan to include 35 patients.

Statistical analysis: At each time-point (baseline, during perfusion, end of sodium lactate infusion), differences of mean MD glucose, lactate, pyruvate, PbtO2, CBF, Mean transit time, ICP, CPP will be analyzed. We will also examine the percentage time spent with abnormal values (MD glucose < 1 mmol/L, PbtO2 < 20 mm Hg, ICP > 20 mm Hg). Differences will be compared using ANOVA for repeated measures.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Hypertonic lactate
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neuroprotective Role of Lactate Therapy in Humans With Traumatic Brain Injury
Actual Study Start Date : March 2012
Actual Primary Completion Date : December 18, 2017
Actual Study Completion Date : December 18, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: sodium lactate infusion
Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
Other: sodium lactate infusion
3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)

Primary Outcome Measures :
  1. Increase from baseline in brain extracellular lactate, pyruvate and glucose [ Time Frame: 6 hours ]
    Increase from baseline in brain extracellular lactate, pyruvate and glucose measured with intra-parenchymal cerebral microdialysis catheter

Secondary Outcome Measures :
  1. Increase from baseline in brain tissue PO2 [ Time Frame: 6 hours ]
    Brain tissue PO2 will be measured with intra-parenchymal probes

  2. Increase from baseline in cerebral perfusion pressure [ Time Frame: 6 hours ]
  3. Decrease from baseline in intracranial pressure [ Time Frame: 6 hours ]
  4. plasma sodium [ Time Frame: 6 hours ]
  5. plasma osmolality [ Time Frame: 6 hours ]
  6. mean CBF, measured by transcranial doppler [ Time Frame: 6 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients admitted to our intensive care unit (ICU) after severe TBI or poor-grade aneurysmal subarachnoid hemorrhage (SAH), defined by a post-resuscitation Glasgow Coma Scale (GCS) < 9
  • Age 18-75 years
  • Abnormal head CT-scan (Marshall grade ≥ 2 or Fisher >2)
  • Intracranial pressure (ICP), PbtO2 and cerebral MD monitoring as part of standard care

Exclusion Criteria:

  • Penetrating TBI
  • non aneurysmal SAH
  • Age < 18 or > 75 years,
  • More than 1 extra-cranial injury with sustained hemodynamic instability and sustained blood lactate elevation > 4 mmol/L
  • Cognitive handicap due to previous neurological or neurosurgical history
  • Non-survivable injury, brain death or expected death within 48 hours
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01573507

Layout table for location information
CHUV, Lausanne University Hospital
Lausanne, Switzerland, 1011
Sponsors and Collaborators
Centre Hospitalier Universitaire Vaudois
Swiss National Science Foundation
European Society of Intensive Care Medicine
Layout table for investigator information
Principal Investigator: Mauro Oddo, MD CHUV, Lausanne University Hospital, Switzerland
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Mauro ODDO, médecin adjoint, PD-MER I, Centre Hospitalier Universitaire Vaudois
ClinicalTrials.gov Identifier: NCT01573507    
Other Study ID Numbers: 237/10
First Posted: April 9, 2012    Key Record Dates
Last Update Posted: September 9, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Mauro ODDO, Centre Hospitalier Universitaire Vaudois:
traumatic brain injury
brain metabolism
cerebral microdialysis
subarachnoid hemorrhage
transcranial doppler
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Injuries, Traumatic
Subarachnoid Hemorrhage
Wounds and Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Pathologic Processes
Intracranial Hemorrhages
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases